Critical Contrast: Lisata Therapeutics (NASDAQ:LSTA) & Bioxytran (OTCMKTS:BIXT)

Bioxytran (OTCMKTS:BIXT) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.

Profitability

This table compares Bioxytran and Lisata Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bioxytran	N/A	N/A	-1,510.01%
Lisata Therapeutics	N/A	-79.04%	-65.79%

Volatility & Risk

Bioxytran has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500.

Insider & Institutional Ownership

8.9% of Lisata Therapeutics shares are owned by institutional investors. 70.0% of Bioxytran shares are owned by insiders. Comparatively, 9.1% of Lisata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Bioxytran and Lisata Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioxytran	N/A	N/A	-$2.37 million	($0.03)	-2.58
Lisata Therapeutics	$1.00 million	17.20	-$19.99 million	($2.13)	-0.92

Bioxytran has higher earnings, but lower revenue than Lisata Therapeutics. Bioxytran is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Bioxytran and Lisata Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioxytran	0	0	0	0	0.00
Lisata Therapeutics	1	1	2	0	2.25

Lisata Therapeutics has a consensus price target of $23.50, suggesting a potential upside of 1,105.13%. Given Lisata Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Lisata Therapeutics is more favorable than Bioxytran.

Summary

Lisata Therapeutics beats Bioxytran on 7 of the 12 factors compared between the two stocks.

About Bioxytran

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.

About Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.